Sponsors

Lead Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

MSD France

PASSION is a french monocentric study. For the retrospective cohort, patient will be selected through the use of data warehouse available on the HEGP. For the prospective cohort, patient will be included according to the selection criteria. Each patient will be followed up during 6 month and a satisfaction questionnaire will be completed at 1 month and 4 month of the first administration of anti-tumor therapy. For both cohort, clinical-anatomo-biological data will be collected through the use of data warehouse available on the HEGP.

Related studies

RECRUITINGPhase 1

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326 · Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, and more

View all related studies →

Integrated Care Pathway in Oncology (PASSION)

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Study for AZD4360 in Participants With Advanced Solid Tumours

Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma

Familial Investigations of Childhood Cancer Predisposition

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Trial snapshot

Condition

Locations shown

For caregivers